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Introduction
Hypertension (HTN) is a global concern and affects 
approximately 75 million adults in the United States and 
if left untreated increases risk of stroke, myocardial 
infarction, vascular disease, and chronic kidney disease.1,2 
Diagnosis and treatment of high blood pressure are 
essential to prevent mortality and morbidity.2,3 
Hypertension may be treated by using routine drugs such 
as angiotensin-converting-enzyme (ACE) inhibitors, beta-
blockers, diuretics, calcium channel blockers, alpha-
blockers, and peripheral vasodilators,3,4 improving 
lifestyle factors including weight loss, quitting smoking, 
reducing sodium intake, regular exercise and limiting 
alcohol consumption.5 These recommendations may be 
used alone or in combination with others4. Losartan is an 
oral medication that belongs to a class of drugs called 
angiotensin receptor blocker (ARBs) which was approved 
by the U.S. Food and Drug Administration (FDA) in April 
1995. Losartan blocks the angiotensin receptor, relaxes 
muscle cells and dilates blood vessels and reduces blood 
pressure.6,7  
Our recent study showed that the OSE is a novel natural 
inhibitor agent and inhibit angiotensin-converting-
enzyme by 80.2 ± 2 % at concentration of 330 μg/ml, and 
exerted antioxidant activity (IC50 value of 2.6 ± 0.04 
mg/ml).8 This plant has been well known under the name 
"Khaje Bashi"9 and has long been used in folk medicine 
as a hypotensive, cardiotonic and diuretic agent.10 Also it 
has been noted in Persian Medicine (PM) literatures as 
diuretic, diaphoretic, antipyretic, analgesic. Cotton thistle 
or Scotch thistle are its common names. It is a flowering 
plant belonging to the Compositae (Asteraceae) family 
and is widely naturalized almost globally, particularly in 
Europe and Western Asia and is a vigorous biennial plant 
with coarse, spiny leaves and conspicuous spiny-winged 
stems.11 In modern medicine, O. acanthium has been 
reported to be a bactericide, cardiotonic, hypotensive and 
hemostatic agent and is used against hypotonicity.12-14 
This species has several bioactive components among 
which sesquiterpene lactones have been found to have 
numerous biological properties including antibacterial, 
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Abstract 
Purpose: Onopordon acanthium L. is known for its medicinal properties. Our recent study 
showed that its seed extract is a novel natura angiotensin-converting-enzyme inhibitor 
(ACEI). This study was carried out to investigate its possible antihypertensive effects in 
patients receiving losartan. 
Methods: This uncontrolled clinical trial was carried out among 20 patients (30-60y) with 
uncontrolled hypertension despite receiving 50 mg losartan (stage I & II) in two hospitals in 
Iran. After completing informed consent, patients were treated by 2 capsules [each 1g of 
Onopordon acanthium seed extract (OSE)] as add-on therapy, two times per day.  
Results: 18 patients completed the study (50.94 ±8.37y). Mean systolic blood pressure (SBP) 
at the baseline was 151.9 ± 13.74mmHg and at the end of the study, it was 134.6 ± 18.25 
mmHg and mean diastolic blood pressure (DBP) was 97.41 ± 10.36 at the baseline and was 
85.71 ± 7.481 after 8 weeks. OSE significantly reduced SBP and DBP at the end of 8 weeks 
(P=0.003, 95% CI: -19.7, -15.1; P=0.0006, 95% CI: -10.23, -13.15; respectively). No 
evidence of hepatic or renal toxicity was detected. 
Conclusion: Based on the results of this study OSE has antihypertensive property with no 
significant adverse effects. However, because of the low number of samples, this medication 
may be not safely administered. The results of this study could be the basis for further studies 
with larger sample size. 
IRCT registration number: IRCT2013020712391N. 
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anti-inflammatory, anti-malarial, and hypotensive 
effects.15 Since the antihypertensive effect of O. 
acanthium seed extract has not been studied on patients in 
follow up of our previous in vitro study, we conducted this 
trial to investigate the possible antihypertensive effects of 
OSE on patients with stage I-II hypertension who were 
under treatment with losartan, a chemical ACE inhibitor, 
as add-on therapy. 
 
Materials and Methods 
Plant material  
O. acanthium L. dried seeds were purchased from the 
local market in Tehran (Grand Bazaar), Iran. The seeds 
were identified by Prof. Gholamreza Amin and were kept 
under the voucher number PMP–714 at the herbarium of 
Faculty of Pharmacy, Tehran University of Medical 
Sciences.  
 
Preparation of the extract and drug formulation  
The extract was prepared in the laboratory of traditional 
pharmacy at faculty of Traditional Medicine, Tehran 
university of medical sciences via maceration method 
using ethanol as the solvent (1:8) at three time points (24, 
48 and 72 h). The three extracts were mixed, filtered and 
evaporated. The total evaporated extract was freeze-dried 
and grinderies to obtain a powder for preparing the 
capsule. Each capsule contained 1g of the freeze-dried 
powder equal to 11 gram of dried seeds, and all the 
physiochemical quality control (QC) tests were performed 
on the capsules.  
 
Toxicology evaluation 
To measure the toxic dose of total extract of OSE (Khaje 
Bashi plant), rats were used and kept at the Animal house 
of the Faculty of Pharmacy, Tehran University of Medical 
Sciences. Animals were kept in standard light (12 hours 
of light and 12 hours of darkness), room temperature (25-
35 °C) with adequate water and food. 12 male albino 
NMRI mice were divided into three groups (4 animals per 
group). The whole extract of the plant was taken in dried 
form and stored in a dark bottle in the refrigerator until it 
was tested. Due to its low solubility, the extract was 
dissolved in dimethyl sulfoxide (DMSO) at a desired 
concentration and diluted with normal saline at a rate of 
1:3 and made as a monotonous suspension. 
The solution was injected intraperitoneally (i.p.). Animals 
received the same amount of DMSO in different dose 
groups. Animals’ condition (lethargy and movement) and 
animal death were investigated for 24-48 hours. In each 
group, mortality rate was reported and plotted against the 
dose used. The dose that causes 50 percent of deaths in 
animals or “Lethal Dose, 50%” (LD50) was calculated 
based on the curve. 
Considering that no studies have been done on the toxicity 
of this plant, in the first step, 0.5, 1, 2, 3.5 and 5 g/kg of 
body weight were used to find the dose range, but no 
mortality or change was observed in animals. In the next 
step, doses of 6-20 g/kg were used, and in dose 20, all 
animals died. In the next stage, the range of 6-13.5 g/kg 
was tested in 6 groups of animals. The results were 
calculated as a percentage of death for each group. LD50 
was calculated using non-linear sigmoid regression and 
Probit method. Meanwhile, the relationship between 
effective dose and effect was analyzed using Pearson's 
relationship and according to the results of these 
experiments, the lethal dose (LD50 value of 8.44 ± 0.04 
g/kg) was determined. According to these results, the 
extract of this plant was classified in "practically non-
poisonous ". 
 
Clinical trial design 
This open-labeled, non-randomized, uncontrolled clinical 
trial, a pilot study, was performed on 20 patients, who 
were under losartan treatment (50mg/d) for at least 6 
weeks before starting the study and their blood pressure 
constantly remained higher than 140/90 (stage I&II) 
hypertension according to the seventh report of the joint 
national committee (JNC VII) report.16 Sample size was 
calculated as follow: based on predicted 14 mmHg 
reduction of systolic blood pressure (d=14) at the end 
point (after 8 weeks), standard deviation 20 (σ=20, power 
80%, confidence interval (CI) of 95% (Z1-α/2=1.96) and 
taking into account a correlation of 0.5 between frequent 
measurements and considering 20 % loss to follow, 20 
patients were enrolled to determine the effective dose of 
therapy. Each individual took 2 capsules, two times a day 
(2 g/BD) and blood pressure was checked every other 
week. If blood pressure has increased more than 15 
mmHg, the patients would have dropped out the study.  
The primary outcome measure was systolic and diastolic 
blood pressure that was measured using aneroid 
sphygmomanometer (F. Bosch, Model: 0123, Germany). 
Metabolic parameters (lipid profile, liver function tests, 
BUN, Cr, FBS) were measured two times during the study 
(at the beginning and at the end of study) at Noor 
laboratory to evaluate the general health status of the 
patients.  
 
Participants 
The patients (30-60 y) were selected from Imam 
Khomeini & Amir-alam hospitals of Tehran University of 
medical sciences. Patients with history of malignant 
hypertension, blood pressure higher than 200/140 mmHg 
and whom needed multi-drug treatment or emergency IV 
drug infusion, history of secondary hypertension, end 
organ damages (EOD), sudden increase of blood pressure 
to greater than 15 mmHg at any time during the study, 
cardiac arrhythmias, symptomatic valvular heart diseases 
(except mitral valve prolapse) were excluded from the 
study. Other exclusion criteria were: diabetes type 1& 2, 
liver disorders, pregnancy breast feeding, cured or 
uncured malignancies during the last 5 years, serum 
potassium >5.2 or <3.5 mEq/L in the first visit, drug or 
alcohol abuse. The procedure was explained to all patients 
and written informed consents were obtained. Patients 
were examined at the beginning of the study and then 
every two weeks, and their arterial blood pressure was 
measured. The researcher's contact number was also 
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provided to patients in order to report any problems 
between every two visits. In addition, patients were asked 
at each session about possible complications such as 
coughing, severe headache, visual impairment, any types 
of arrhythmias, and orthostatic hypotension, and were 
recorded. Demographic and baseline data, medical history 
and any concomitant medications of enrolled patients 
were recorded. The study protocol was approved by the 
ethics committee of Research Institute for Islamic and 
Complementary Medicine of Iran University of Medical 
Sciences at 09/10/2012 with reference number 
732/P26/M/T. 
 
Statistical methods 
The changes in blood pressure were analyzed using 
repeated measures ANOVA analysis. P value <0.05 was 
considered significant. The LD50 was calculated using 
nonlinear sigmoid regression and Probit technique. 
Moreover, the correlation between effect and administered 
dose was analyzed using Pearson correlation test. 
 
Results and Discussion 
Cytotoxicity of the extract was performed in mice by 
injecting different doses of OSE (0.5-13.5 g/kg) to 
measure the minimum toxic dose of OSE and LD50 was 
8.44 ± 0.04 g/kg. Sampling began on May 21, 2013 and 
continued for five months, till October 23, 2013. 54 
patients were assessed. Only 24 patients met the inclusion 
criteria whom four were not willing to participate in the 
study. At the end, 18 patients (of 20) completed the study 
and two patients were left the study due to increased blood 
pressure more than 160/100 mmHg in one patient after 2 
days and another, after 3 days from starting point. Based 
on the ethical issues and respect to the patients’ right, they 
were excluded and researcher referred both of them to the 
cardiologist to be treated with two or more drugs (Figure 1). 
 
 
Figure 1. The trial flowchart 
Patients took 2 capsules two times a day (2 g/BD) and were 
visited every other week and systolic and diastolic blood 
pressure and any possible side effects were recorded (Table 1). 
 
Table 1. Blood pressure changes (before and after the study) 
Blood pressure(mmHg) Time Mean ± SD 
Systolic blood pressure (SBP) 
at baseline 151.9 ± 13.74 
after 8 weeks 134.6 ± 18.25 
Diastolic blood pressure (DBP) 
at baseline 97.41 ± 10.36 
after 8 weeks 85.71 ± 7.48 
 
After treatment for at least 8 weeks, systolic and diastolic 
blood pressure decreased significantly (P=0.003, 95% CI: 
-19.7, -15.1; P=0.0006, 95% CI: -10.23, -13.15; 
respectively) (Table 2). Moreover systolic and diastolic 
blood pressure decreased after 45 days treatment 
(P=0.025, 95% CI: -15.4, -10.6; P=0.034, 95% CI: -7.71, 
-7.85; respectively). At the end of the study, OSE 
decreased systolic and diastolic blood pressure 17.3 and 
11.7 mmHg, respectively. (Figure 2, A & B).  
 
Table 2. Baseline characteristics of participants and changes in 
systolic and diastolic BP. 
Demographic characteristics 
Age y (mean ± SD) 50.94 ± 8.73 
BMI kg/m2 (mean ± SD) 30.4 ± 4.84 
Male n (%) 7 ( 35) 
Sample size n 20 
Blood pressure(mmHg) 
Systolic blood pressure (SBP) 
After 2 weeks ~ -11 
After 4 weeks ~ -9.9 
After 6 weeks ~ -13 
After 8 weeks ~ -17.3 
Diastolic blood pressure 
(DBP) 
After 2 weeks ~ -4.3 
After 4 weeks ~ -4.59 
After 6 weeks ~ -7.79 
After 8weeks ~ -11.7 
 
We did not observe hepatic or renal toxicity as the result 
of O. acanthium extract consumption in patients during 
the study. 
The results of these tests showed no significant changes 
(CBC, FBS, TG, Chol, LDL, HDL, SGOT, SGPT, BUN, 
Cr). As shown in the following diagrams, although these 
changes were not significant, in some cases, such as 
glucose, cholesterol, triglyceride, LDL, VLDL, and BUN, 
there was a tendency to reduction. Based on these results, 
HDL levels show a modest increase. The levels of sodium 
and creatinine were almost constant. The amount of 
potassium and liver enzymes were in the normal range 
(Figures 3 & 4). In general the changes of liver enzymes 
levels before and after treatment was not significant 
(P=0.1481; P=0.1400, respectively) (Figure 5). 
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Figure 2. Blood pressure changes during treatment. Systolic (A) and diastolic blood pressures (B) have been measured at multiple 
time points: on the first day of investigation, 15, 30, 45, and 60 days after treatment (mean ± SEM). Decline of blood pressure at different 
time points have been compared with the blood pressure at the beginning of the investigation. There was a significant decline of blood 
pressure beyond 45 days of treatment when compared with the blood pressure before treatment (the asterisks indicate P < 0.05,  
repeated measures ANOVA analysis). 
 
  
 
Figure 3. Changes in metabolic factors compared with the beginning of the intervention. After analysis, student t-test did not change 
significantly. P <0.05 was considered as a significant level. 
 
Regarding the side effects, we detected mild dyspnea in 
two patients after 2 weeks. Also two patients showed 
dizziness and feeling of heaviness in the head in the first 
month of treatment that resolved later.  
These data indicated that 4 g/day of O. acanthium seed 
extract for 8 weeks significantly decreases systolic and 
diastolic blood pressure in patients with stage I and II 
primary essential hypertension under losartan treatment. 
In line with our recent findings in which a novel 
compound was extracted and identified from O. 
acanthium named Onopordia, OSE showed antioxidant 
and angiotensin converting enzyme inhibitor (ACEI) 
activity (80.2 ± 2 %). Its potential of blood pressure 
decreasing can be due to its different components such as 
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sesquiterpenes and flavonoid.8 There is no study on 
evaluating the effects of O. acanthium on blood pressure; 
however, some studies around the world have evaluated 
the hypotensive effect of some popular and well-known 
hypotensive herbal medicines. 
 
 
Figure 4. Changes in electrolytes and renal tests compared with the beginning of the intervention. After analysis, student t-test did not 
change significantly. P <0.05 was considered as a significant level.
 
 
Figure 5. Changes in the liver function tests compared to the beginning of the intervention. After analysis, student t-test did not change 
significantly. P <0.05 was considered as a significant level. 
 
Asgary et al., in a study in Iran, administered Achillea 
wilhelmsii to 120 patients for 8 weeks and showed 
significant decline of systolic and diastolic blood pressure 
(P=0.005 and P=0.003, respectively).17 Walker et al., 
administered 500 mg/day of dried, full-spectrum aqueous-
alcoholic extract of hawthorn (Crataegus laevigata) 
leaves and flowers to 36 patients with essential HTN for 
10 weeks and found that diastolic blood pressure 
decreased in 19 patients. However the difference was not 
significant (P=0.08).18 In a follow up study Walker et al., 
evaluated the hypotensive effect of Crataegus laevigata, 
1200mg/day for 16 weeks on 76 patients and indicated 
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significant decrease in diastolic (P=0.03) but no 
significant decrease in systolic blood pressure (P=0.32).19 
Consistent with these findings Ried, et al. indicated that 
treatment with aged garlic extract for 12 weeks lowered 
systolic blood pressure 10.2 mmHg.20 Furthermore 
Susalit, et al., investigated the hypotensive effect of olive 
(Olea europaea) leaf extract, 500 mg/daily for 8 weeks on 
232 patients and indicated the extract lowered 10 mmHg 
systolic blood pressure.21 Moreover, several other herbal 
agents were studied independently and showed 
hypotensive effect. Examples are Sour Cherry (Prunus 
cerasus L.), Nigella sativa seed extract, pomegranate 
juice, Hibiscus sabdariffa and canola oil with sunflower 
oil.22-29 In this study, OSE lowered systolic blood pressure 
by 17.3 mmHg that is more potent than all studied 
hypotensive agents. Similar effects have been reported 
about aged garlic extract and olive leaf extract that showed 
a reduction of about 10 mmHg of systolic blood pressure. 
The reasons for such discripency is not clear but it may be 
due to the presence of both ACEI and diuretic activity in 
OSE. This finding was in line with previous report by 
Sharifi, et al., that revealed OSE has more hypotensive 
effect than other 50 herbal agents which has been 
assessed.8 
Several limitations are inherent to the present study. 
Recruiting hypertensive patients categorized in the first 
and second stage of hypertension who were also treated 
with losartan was very difficult. The majority of 
hypertensive patients had to use two or more drugs to 
control their blood pressure, due to lack of good response 
to one-drug therapy. The limitation of recruiting 
hypertensive patients in this study was consistent with the 
one in the other studies. The withdrawal of the patients 
was also an obstacle to obtain the desired results with 
higher power of analysis.  
 
Conclusion 
OSE synergistically with diuretic and plasma ACE 
inhibitor activity reduced blood pressure (both systolic 
and diastolic) in the patients under treatment with losartan, 
and did not show remarkable side effects in patients with 
primary hypertension. Because of the low number of 
samples, this medication may be not safely recommended. 
Further clinical trials is needed for increasing certainty 
with larger sample size and placebo. 
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